Covid Vaccine Race

The deaths occurred this month in Japan, and investigations into the deaths and the vaccine batches are ongoing.

The Centers for Disease Control and Prevention (CDC) released data this week that showed greater breakthrough infections in a large study mainly compiled before the emergence of Delta as the predominant variant in the US.

An Israel study estimates vaccinated persons' risk of side effects including myocarditis, relative to the risk brought on by SARS-CoV-2 infection.

A new report says the public health officials within the Biden Administration are preparing for making the interim period closer together.

The submission comes day after BNT162b2 became the first fully approved COVID-19 vaccine by the FDA.

The company announced it filed its submission to prevent COVID-19 in individuals 18 years of age and older.

August is National Immunization Month. With the FDA’s approval of the Pfizer-BioNTech COVID-19 vaccine, providers will likely be having more conversations with patients on the topic. Motivational interviewing is an emerging strategy for providers to consider in their conversations with patients who are reluctant to get the vaccine.

An extra dose generated a rapid and robust increase in antibodies.

Study comparing mRNA shots finds variability in response, though both generally safe and effective.

David Weber, MD, MPH, explains what portion of the population may buy into the newly approved Pfizer-BioNTech vaccine.

With the full FDA approval of the Pfizer-BioNTech COVID-19 vaccine, Mark McClellan, MD, PhD, says more employer mandates will likely be coming, but he does not see federal government intervention in this area.

The most common adverse event was myocarditis, which was reported in nearly 500 patients. None of those patients had died as of the new analysis, and the rate per million cases was 3.5 cases.

The full approval for BNT162b2 will afford physicians greater prescribing capability, and will likely drive workplace vaccine mandates.

The decision on the final federal approval in the US could mean many more people would get the vaccine.

The World Health Organization (WHO) announces the Solidarity PLUS platform trial of drugs repurposed to treat COVID-19 after Solidarity trial candidates disappoint.

The US federal government announces plans for mRNA COVID-19 vaccine booster doses, and more children and teens are getting hospitalized for the virus.

Common cloth and surgical masks allow for the build-up of aerosol droplets over time.

While an association was found, the adverse events are very rare.

All Americans who received either Pfizer or Moderna will be eligible 8 months after their second dose.

The Biden administration reportedly hopes for FDA-authorized booster doses for the adult general population in the next month.

The US is targeting a possible Fall rollout of publicly available doses, yet experts debate their current necessity.

Fewer than 10,000 adverse events among more than 8.9 million doses administered.

The Centers for Disease Control and Prevention (CDC) endorses the additional COVID-19 vaccine shot in immunocompromised people.

A quartet of infectious disease, vaccinology, and virology experts share thoughts on the FDA's newest emergency authorization for COVID-19 mRNA vaccines.

"Humans dislike change, especially when it is rapid, unexpected, or negative. Delta is all 3."

Donald Alcendor, PhD, shares expert perspective on the newest FDA authorization, as well as what a full COVID-19 vaccine approval would mean for US immunization.

The move will offer an extra boost of immunity for patients with compromised immune systems, including organ transplant recipients.

An England study shows the Pfizer-BioNTech and AstraZeneca vaccines remain effective in reducing symptomatic disease risk.

The Food and Drug Administration (FDA) is expected to expand the Emergency Use Authorization (EUA) of the Pfizer-BioNTech and Moderna vaccines for a third dose in those who might be vulnerable to COVID-19.

The vaccine demonstrated an acceptable safety profile in the adolescent population.